Related Experiment Video
Updated: Jul 17, 2026
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2
1University of Tübingen, Department of Radiation Oncology, Hoppe-Seyler-Str 3, D-72076, Tübingen, Germany. patrizia.marini@uni-tuebingen.de
Abstract:
Human Genome Sciences Inc, under license from Cambridge Antibody Technology Ltd, is developing lexatumumab, an intravenous human agonistic mAb to TNF-related apoptosis-inducing ligand (TRAIL) receptor 2, for the potential treatment of cancer. Phase II clinical trials of lexatumumab are underway.
Insights
Lexatumumab, a novel antibody therapy, is being investigated for cancer treatment. This human monoclonal antibody targets a specific cell death pathway, with ongoing Phase II clinical trials.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Cancer treatment remains a significant challenge, necessitating novel therapeutic strategies.
- Targeting programmed cell death pathways is a promising approach in oncology.
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 is a key mediator of apoptosis.
Purpose of the Study:
- To evaluate the safety and efficacy of lexatumumab in cancer patients.
- To investigate lexatumumab as a potential anti-cancer therapeutic agent.
Main Methods:
- Lexatumumab is an intravenous human agonistic monoclonal antibody (mAb).
- It targets the TNF-related apoptosis-inducing ligand (TRAIL) receptor 2.
- Phase II clinical trials are currently being conducted.
Main Results:
- Phase II clinical trials are underway, indicating early-stage investigation.
- Results from these trials will determine the therapeutic potential of lexatumumab.
Conclusions:
- Lexatumumab shows potential as a novel cancer treatment.
- Further clinical evaluation is required to establish its role in oncology.
